A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus

PLoS Neglected Tropical Diseases

Volumn 11, Issue 6, 2017, Pages

  Magnani, Diogo M ^a   Silveira, Cassia G T ^b   Rosen, Brandon C ^a   Ricciardi, Michael J ^a   Pedreño Lopez, Núria ^a   Gutman, Martin J ^a   Bailey, Varian K ^a   Maxwell, Helen S ^a   Domingues, Aline ^a   Gonzalez Nieto, Lucas ^a   Avelino Silva, Vivian I ^c   Trindade, Mateus ^b,c   Nogueira, Juliana ^d   Oliveira, Consuelo S ^e   Maestri, Alvino ^b   Felix, Alvina Clara ^b   Levi, José Eduardo ^b   Nogueira, Mauricio L ^f   Martins, Mauricio A ^a   Martinez Navio, José M ^a   Fuchs, Sebastian P ^a   Whitehead, Stephen S ^g   Burton, Dennis R ^h,i   Desrosiers, Ronald C ^a   Kallas, Esper G ^b   Watkins, David I ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

^e INSTITUTO EVANDRO CHAGAS   (Brazil)

^f FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h SCRIPPS RESEARCH INSTITUTE   (United States)

ⁱ HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; AFFINITY MATURATION; ANTIBODY PRODUCTION; ANTIBODY PURIFICATION; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DENGUE; DENGUE VIRUS; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; GERMLINE GENE; GERMLINE MUTATION; GUILLAIN BARRE SYNDROME; HUMAN; MATURATION; MIDDLE AGED; NEUTRALIZATION ASSAY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLAQUE REDUCTION NEUTRALIZATION TEST; PLASMABLAST; PLASMABLAST SORTING; PREGNANT WOMAN; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC HYPERMUTATION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; ZIKA VIRUS; AMINO ACID SEQUENCE; BLOOD; GENETICS; IMMUNOLOGY; MALE; VIROLOGY; ZIKA FEVER;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FLOW CYTOMETRY; GERM-LINE MUTATION; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85021339566     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005655     Document Type: Article

References (73)

1. Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, Diallo M, et al. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl Trop Dis. 2014;8(1):e2636. doi: 10.1371/journal.pntd.0002636 24421913; PubMed Central PMCID: PMC3888466.
2. Boorman JP, Porterfield JS, A simple technique for infection of mosquitoes with viruses; transmission of Zika virus. Trans R Soc Trop Med Hyg. 1956;50(3):238–42. 13337908.
3. Haddow AJ, Williams MC, Woodall JP, Simpson DI, Goma LK, Twelve Isolations of Zika Virus from Aedes (Stegomyia) Africanus (Theobald) Taken in and above a Uganda Forest. Bull World Health Organ. 1964;31:57–69. 14230895; PubMed Central PMCID: PMC2555143.
4. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–43. doi: 10.1056/NEJMoa0805715 19516034.
5. Hayes EB, Zika virus outside Africa. Emerg Infect Dis. 2009;15(9):1347–50. doi: 10.3201/eid1509.090442 19788800; PubMed Central PMCID: PMC2819875.
6. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14(8):1232–9. doi: 10.3201/eid1408.080287 18680646; PubMed Central PMCID: PMC2600394.
7. Dyer O, Zika virus spreads across Americas as concerns mount over birth defects. BMJ. 2015;351:h6983. doi: 10.1136/bmj.h6983 26698165.
8. Gatherer D, Kohl A, Zika virus: a previously slow pandemic spreads rapidly through the Americas. J Gen Virol. 2016;97(2):269–73. doi: 10.1099/jgv.0.000381 26684466.
9. Hennessey M, Fischer M, Staples JE, Zika Virus Spreads to New Areas—Region of the Americas, May 2015-January 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):55–8. doi: 10.15585/mmwr.mm6503e1 26820163.
10. Brasil P, Pereira JP, Jr.Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. The New England journal of medicine. 2016;375(24):2321–34. doi: 10.1056/NEJMoa1602412 26943629.
11. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, et al. Zika Virus Outbreak in Rio de Janeiro, Brazil: Clinical Characterization, Epidemiological and Virological Aspects. PLoS neglected tropical diseases. 2016;10(4):e0004636. doi: 10.1371/journal.pntd.0004636 27070912; PubMed Central PMCID: PMC4829157.
12. Honein MA, Dawson AL, Petersen EE, Jones AM, Lee EH, Yazdy MM, et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA: the journal of the American Medical Association. 2016. doi: 10.1001/jama.2016.19006 27960197.
13. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. The Lancet infectious diseases. 2016;16(6):653–60. doi: 10.1016/S1473-3099(16)00095-5 26897108.
14. de Paula Freitas B, de Oliveira Dias JR, Prazeres J, Sacramento GA, Ko AI, Maia M, et al. Ocular Findings in Infants With Microcephaly Associated With Presumed Zika Virus Congenital Infection in Salvador, Brazil. JAMA Ophthalmol. 2016. doi: 10.1001/jamaophthalmol.2016.0267 26865554.
15. Martines RB, Bhatnagar J, de Oliveira Ramos AM, Davi HP, Iglezias SD, Kanamura CT, et al. Pathology of congenital Zika syndrome in Brazil: a case series. Lancet. 2016. doi: 10.1016/S0140-6736(16)30883-2 27372395.
16. Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L, Muehlenbachs A, Gary J, et al. Notes from the Field: Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(6):159–60. doi: 10.15585/mmwr.mm6506e1 26890059.
17. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika Virus Associated with Microcephaly. The New England journal of medicine. 2016;374(10):951–8. doi: 10.1056/NEJMoa1600651 26862926.
18. Mor G, Placental Inflammatory Response to Zika Virus may Affect Fetal Brain Development. Am J Reprod Immunol. 2016;75(4):421–2. doi: 10.1111/aji.12505 26892436.
19. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM, Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg?Ultrasound Obstet Gynecol. 2016;47(1):6–7. doi: 10.1002/uog.15831 26731034.
20. Sarno M, Sacramento GA, Khouri R, do Rosario MS, Costa F, Archanjo G, et al. Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl Trop Dis. 2016;10(2):e0004517. doi: 10.1371/journal.pntd.0004517 26914330; PubMed Central PMCID: PMC4767410.
21. Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, et al. Possible Association Between Zika Virus Infection and Microcephaly—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(3):59–62. doi: 10.15585/mmwr.mm6503e2 26820244.
22. Staples JE, Dziuban EJ, Fischer M, Cragan JD, Rasmussen SA, Cannon MJ, et al. Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus Infection—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):63–7. doi: 10.15585/mmwr.mm6503e3 26820387.
23. Petersen EE, Staples JE, Meaney-Delman D, Fischer M, Ellington SR, Callaghan WM, et al. Interim Guidelines for Pregnant Women During a Zika Virus Outbreak—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(2):30–3. doi: 10.15585/mmwr.mm6502e1 26796813.
24. Oster AM, Brooks JT, Stryker JE, Kachur RE, Mead P, Pesik NT, et al. Interim Guidelines for Prevention of Sexual Transmission of Zika Virus—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(5):120–1. doi: 10.15585/mmwr.mm6505e1 26866485.
25. McCarthy M, US health officials investigate sexually transmitted Zika virus infections. BMJ. 2016;352:i1180. doi: 10.1136/bmj.i1180 26921165.
26. McCarthy M, Zika virus was transmitted by sexual contact in Texas, health officials report. BMJ. 2016;352:i720. doi: 10.1136/bmj.i720 26848011.
27. Oduyebo T, Petersen EE, Rasmussen SA, Mead PS, Meaney-Delman D, Renquist CM, et al. Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(5):122–7. doi: 10.15585/mmwr.mm6505e2 26866840.
28. Likos A, Griffin I, Bingham AM, Stanek D, Fischer M, White S, et al. Local Mosquito-Borne Transmission of Zika Virus—Miami-Dade and Broward Counties, Florida, June-August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(38):1032–8. doi: 10.15585/mmwr.mm6538e1 27684886.
29. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53. doi: 10.1038/nature13777 25171469; PubMed Central PMCID: PMC4214273.
30. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–42. doi: 10.1126/science.aad5224 26917593.
31. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–4. doi: 10.1038/nature06106 17805298.
32. Eisen HN, Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses. Cancer Immunol Res. 2014;2(5):381–92. doi: 10.1158/2326-6066.CIR-14-0029 24795350.
33. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H, Autoreactivity in human IgG+ memory B cells. Immunity. 2007;26(2):205–13. doi: 10.1016/j.immuni.2007.01.009 17306569; PubMed Central PMCID: PMC1839941.
34. West AP, Jr.Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC, Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156(4):633–48. doi: 10.1016/j.cell.2014.01.052 24529371; PubMed Central PMCID: PMC4041625.
35. Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature's pathways. Immunological reviews. 2013;254(1):225–44. doi: 10.1111/imr.12075 23772623; PubMed Central PMCID: PMC3738265.
36. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC, Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–204. doi: 10.1126/science.1241144 24031012; PubMed Central PMCID: PMC3970325.
37. Burton DR, Hangartner L, Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annual review of immunology. 2016;34:635–59. doi: 10.1146/annurev-immunol-041015-055515 27168247.
38. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. doi: 10.1016/j.cell.2013.03.018 23540694; PubMed Central PMCID: PMC3792590.
39. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390(3):404–9. doi: 10.1016/j.bbrc.2009.09.029 19748484; PubMed Central PMCID: PMC2787893.
40. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS pathogens. 2013;9(11):e1003754. doi: 10.1371/journal.ppat.1003754 24278016; PubMed Central PMCID: PMC3836729.
41. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, et al. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell. 2016;165(2):449–63. doi: 10.1016/j.cell.2016.02.022 26949186; PubMed Central PMCID: PMC4826291.
42. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–6. doi: 10.1126/science.aaf8505 27417494.
43. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(28):7852–7. doi: 10.1073/pnas.1607931113 27354515; PubMed Central PMCID: PMC4948328.
44. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nature immunology. 2015;16(2):170–7. doi: 10.1038/ni.3058 25501631; PubMed Central PMCID: PMC4445969.
45. Wang Q, Yang H, Liu X, Dai L, Ma T, Qi J, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science translational medicine. 2016;8(369):369ra179. doi: 10.1126/scitranslmed.aai8336 27974667.
46. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H, Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of immunological methods. 2008;329(1–2):112–24. doi: 10.1016/j.jim.2007.09.017 17996249; PubMed Central PMCID: PMC2243222.
47. Ye J, Ma N, Madden TL, Ostell JM, IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic acids research. 2013;41(Web Server issue):W34–40. doi: 10.1093/nar/gkt382 23671333; PubMed Central PMCID: PMC3692102.
48. Giudicelli V, Brochet X, Lefranc MP, IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc. 2011;2011(6):695–715. doi: 10.1101/pdb.prot5633 21632778.
49. de Alwis R, de Silva AM, Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. Methods in molecular biology. 2014;1138:27–39. doi: 10.1007/978-1-4939-0348-1_3 24696329.
50. Kraus AA, Messer W, Haymore LB, de Silva AM, Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. Journal of clinical microbiology. 2007;45(11):3777–80. doi: 10.1128/JCM.00827-07 17804661; PubMed Central PMCID: PMC2168473.
51. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. The American journal of tropical medicine and hygiene. 2001;65(5):405–13. 11716091.
52. Lefranc MP, Pommie C, Ruiz M, Giudicelli V, Foulquier E, Truong L, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol. 2003;27(1):55–77. 12477501.
53. Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, Geley S, et al. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity. 1996;5(6):639–52. 8986722.
54. Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, et al. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. The Journal of clinical investigation. 2016;126(4):1482–94. doi: 10.1172/JCI85317 26950424; PubMed Central PMCID: PMC4811156.
55. Kato M, Tsuji-Kawahara S, Kawasaki Y, Kinoshita S, Chikaishi T, Takamura S, et al. Class switch recombination and somatic hypermutation of virus-neutralizing antibodies are not essential for control of friend retrovirus infection. Journal of virology. 2015;89(2):1468–73. doi: 10.1128/JVI.02293-14 25378499; PubMed Central PMCID: PMC4300674.
56. Godoy-Lozano EE, Tellez-Sosa J, Sanchez-Gonzalez G, Samano-Sanchez H, Aguilar-Salgado A, Salinas-Rodriguez A, et al. Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response. Genome Med. 2016;8(1):23. doi: 10.1186/s13073-016-0276-1 26917418; PubMed Central PMCID: PMC4766701.
57. Kalinke U, Oxenius A, Lopez-Macias C, Zinkernagel RM, Hengartner H, Virus neutralization by germ-line vs. hypermutated antibodies. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(18):10126–31. 10963674; PubMed Central PMCID: PMC27744.
58. Takemori T, Kaji T, Takahashi Y, Shimoda M, Rajewsky K, Generation of memory B cells inside and outside germinal centers. European journal of immunology. 2014;44(5):1258–64. doi: 10.1002/eji.201343716 24610726.
59. Roost HP, Bachmann MF, Haag A, Kalinke U, Pliska V, Hengartner H, et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(5):1257–61. 7877965; PubMed Central PMCID: PMC42498.
60. Hangartner L, Zinkernagel RM, Hengartner H, Antiviral antibody responses: the two extremes of a wide spectrum. Nature reviews Immunology. 2006;6(3):231–43. doi: 10.1038/nri1783 16498452.
61. Wakerley BR, Uncini A, Yuki N, Group GBSCGroup GBSCGuillain-Barre and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44. doi: 10.1038/nrneurol.2014.138 25072194.
62. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD, Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 1991;86(2):192–8. 1934588; PubMed Central PMCID: PMC1554132.
63. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. Journal of virology. 2012;86(6):2911–8. doi: 10.1128/JVI.06075-11 22238318; PubMed Central PMCID: PMC3302324.
64. Fink K, Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Frontiers in immunology. 2012;3:78. doi: 10.3389/fimmu.2012.00078 22566959; PubMed Central PMCID: PMC3341968.
65. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. Journal of virology. 2010;84(18):9227–39. doi: 10.1128/JVI.01087-10 20592088; PubMed Central PMCID: PMC2937608.
66. Davidson E, Doranz BJ, A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology. 2014;143(1):13–20. doi: 10.1111/imm.12323 24854488; PubMed Central PMCID: PMC4137951.
67. Sapparapu G, Fernandez E, Kose N, Bin C, Fox JM, Bombardi RG, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443–7. doi: 10.1038/nature20564 27819683.
68. Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA, Rose L, et al. Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR Morb Mortal Wkly Rep. 2016;65(21):543–6. doi: 10.15585/mmwr.mm6521e1 27254248.
69. Fields BN, Knipe DM, Howley PM, Fields virology. 5th ed.Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
70. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016. doi: 10.1038/nature18938 27338953.
71. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection. Science. 2016. doi: 10.1126/science.aaf8505 27417494.
72. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M, High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses. Euro Surveill. 2016;21(16). doi: 10.2807/1560-7917.ES.2016.21.16.30203 27126052.
73. Speer SD, Pierson TC, VIROLOGY. Diagnostics for Zika virus on the horizon. Science. 2016;353(6301):750–1. doi: 10.1126/science.aah6187 27540152.